Stereotactic Radiosurgery Articles

BERKELEY, CA (UroToday.com) - Peter W. Hanson and colleagues at The Gamma Knife of Spokane (Spokane, WA) have recently published a concise review on the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases.

Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer.

Molecular profiles of renal cell carcinoma (RCC) brain metastases (BMs) are not well characterized. Effective management with locoregional therapies, including stereotactic radiosurgery (SRS), is critical as systemic therapy advancements have improved overall survival (OS).

Intraventricular metastatic brain tumors account for a small but challenging fraction of metastatic brain tumors (0.9-4.5%). Metastases from renal cell carcinoma (RCC) account for a large portion of these intraventricular tumors, and while patient outcomes are assumed to be poor, these have not been reported in a modern series with a multimodality treatment paradigm including radiation, resection and CSF diversion.

Brain metastases from bladder cancer are rare and published outcomes data are sparse. To date, no institutions have reported a series of patients with brain metastases from bladder cancer treated with stereotactic radiosurgery (SRS).

Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized.

Brain metastases arising from prostate cancer are exceedingly rare and typically occur late in the course of the disease. Most patients have widespread metastatic disease before developing brain metastases from prostate cancer.

The use of stereotactic ablative radiotherapy for recurrent and metastatic renal cell carcinoma (RCC) is not yet standard treatment due to uncertainties regarding its efficacy and safety.

The objective of the systematic review and meta-analysis was to assess the efficacy and safety of stereotactic radiotherapy for metastatic RCC.

As novel therapies improve survival for men with prostate cancer, intracranial metastatic disease has become more common. The purpose of this multicenter study was to evaluate the safety and efficacy of stereotactic radiosurgery (SRS) in the management of intracranial prostate cancer metastases.